Structured evidence table for Resveratrol Cardiovascular Meta-Analysis, generated from 3 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resveratrol Cardiovascular Meta-Analysis | Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. | 1 | Sun JN (2026) | Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. |
| Resveratrol Cardiovascular Meta-Analysis | Resveratrol (RSV), a bioactive polyphenol, has emerged as a pleiotropic modulator within the integrated pathophysiology of cardiovascular disease (CVD) across the life course. | 4 | Hsu CN (2026) | Resveratrol and Redox Regulation in Cardiovascular Disease Across the Life Course: Mechanistic and Translational Perspectives. |
| Resveratrol Cardiovascular Meta-Analysis | Effective CVD management requires a transition from organ-centric frameworks to systems-level models that acknowledge dynamic crosstalk among metabolic, renal, and cardiovascular networks. | 4 | Hsu CN (2026) | Resveratrol and Redox Regulation in Cardiovascular Disease Across the Life Course: Mechanistic and Translational Perspectives. |
| Resveratrol Cardiovascular Meta-Analysis | Background/aim Resveratrol, a polyphenolic compound found in grapes, berries, and peanuts, has been linked to antioxidant, anti-inflammatory, and vasoprotective effects. | 4 | Shen CY (2026) | Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. |
| Resveratrol Cardiovascular Meta-Analysis | Yet, evidence from randomized controlled trials (RCTs) remains inconsistent, and the quality, dosage, and cost of commercial resveratrol products vary considerably, raising uncertainty about their true efficacy. | 4 | Shen CY (2026) | Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. |
| Resveratrol Cardiovascular Meta-Analysis | Materials and methods We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for RCTs published up to July 2025 that evaluated resveratrol supplementation in adults with obesity-related metabolic disorders or associated risk factors. | 4 | Shen CY (2026) | Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. |
Source documents